Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often?

J Ciampolini, K G Harding

Abstract
In this review the pathophysiology of chronic bacterial osteomyelitis is summarised, focusing on how bacteria succeed so often in overcoming both host defence mechanisms and antibiotic agents. Bacteria adhere to bone matrix and orthopaedic implants via receptors to fibronectin and to other structural proteins. They subsequently elude host defences and antibiotics by “hiding” intracellularly, by developing a slimy coat, or by acquiring a very slow metabolic rate. The presence of an orthopaedic implant also causes a local polymorphonuclear cell defect, with decreased ability to kill phagocytosed bacteria. Osteolysis is determined locally by the interaction of bacterial surface components with immune system cells and subsequent cytokine production. The increasing development of antibiotic resistance by Staphylococcus aureus and S epidermidis will probably make conservative treatment even less successful than it is now. A close interaction between orthopaedic surgeons and physicians, with combined medical and operative treatment, is to be commended.

Keywords: osteomyelitis; joint replacement infection; antibiotics; osteolysis

Acute bacterial osteomyelitis carried a 50% mortality in the preantibiotic era because of overwhelming sepsis with metastatic abscesses. Although antimicrobial drugs have dramatically changed the prognosis of the acute haematogenous form, chronic bacterial osteomyelitis remains a challenging medical problem. Despite advances in antibiotic development, it all too often remains refractory to chemotherapeutic treatment alone. The rapid development of antibiotic resistance by Staphylococcus spp will probably demand more frequently a strategy of combined medical and surgical treatment in the near future.

In this review we analyse the current understanding of chronic osteomyelitis by focusing on how bacteria succeed in overcoming both host defence mechanisms and the antibiotic agents.

Discharging sinus and the underlying bone: micro-organisms involved
A clinician treating a patient with a suspected infected wound will usually send a superficial pus swab to the laboratory and institute antibiotic therapy accordingly. Particular problems, however, exist for wounds that are in fact sinuses overlying a focus of chronic osteomyelitis. Mackowiack in 1978 demonstrated the low positive predictive value of sinus tract swabs; in a retrospective analysis of 40 patients, only 44% of the soft tissue swabs contained the same pathogen as that obtained from a bone sample at the time of operation. However, isolation of Staphylococcus aureus from the sinus tract swab had a higher positive predictive value than for other bacteria (78%). The same study found 60% of chronic osteomyelitis to be due to S aureus, followed by enterobacteriaceae (23%), pseudomonas (9%) and streptococcus (9%). Similar results with regards to the inaccuracy of wound swabs were obtained in prospective studies on diabetic foot infection and on post-traumatic chronic osteomyelitis.

The latter study also demonstrated the poor positive predictive value of Craig needle biopsy specimens. Accurate identification of the micro-organism and its sensitivity can therefore only be obtained by an open surgical procedure, and there appears little (if any at all) place for non-invasive diagnostic methods.

From cultures of operative specimens, S aureus is the main causative agent of chronic bacterial osteomyelitis, accounting for about two thirds of the isolates, followed by pseudomonas and enterobacteriaceae. Osteomyelitis complicating diabetic foot infection, however, is typically polymicrobial, with mixed aerobes, facultative anaerobes, and strict anaerobes being isolated at operation. Coagulase negative Staphylococcus spp, such as S epidermidis, are responsible for the majority of chronic osteomyelitis associated with orthopaedic implants and for 90% of pin tract infections. Other less common micro-organisms isolated include salmonella (more frequent in developing countries), and anaerobes such as clostridium and Pasteurella multocida.

Box 1 summarises the above section.

Box 1: Micro-organisms
- The typical causative agent is S aureus, or S epidermidis if associated with an implant. Gram negative bacteria are present in about one third of cases.
- Chronic osteomyelitis in the diabetic foot is polymicrobial with mixed Gram positive and Gram negative bacteria (aerobes and anaerobes).
- Wound swabs are all too often inaccurate in chronic osteomyelitis: cultures from operative specimens are a more reliable method of planning antibiotic treatment.
Pathophysiology of bone infection
Rodet produced the first experimental acute haematogenous osteomyelitis in 1884: injection of rabbits with “un micrococcus qu’il possede une couleur jaune orange” (S aureus) resulted in the occurrence of multiple bone abscesses. Since then various animal models have been studied, including rodents, chicks, rabbits, dogs and, more recently, sheep. The development and progression of the disease can be summarised in bacterial contamination and adhesion followed by infection and subsequent chronicity. Patient predisposing factors intervene at various levels (fig 1).

PATIENT PREDISPOSING FACTORS
Healthy bone tissue is extremely resistant to infection. The presence of bone necrosis, heavy contamination or foreign bodies, as well as general predisposing factors such as diabetes and peripheral vascular disease tip the balance in favour of the bacterium.

Trauma or surgery can produce devitalised bone fragments. The other single most potent bone necrotising factor is indeed ischaemia. In the chick model of haematogenous osteomyelitis, patchy ischaemic bone necrosis occurs when the infective process occludes the vascular tunnels. This creates an ideal culture medium for bacteria, and at 48 hours, abscesses are formed. A sequestrum develops within eight days.

The role of bone necrosis is pivotal to the establishment of experimental chronic osteomyelitis by direct inoculum: Norden and Kennedy in 1970 used intramedullary sodium morrhuate, a sclerosing agent, before direct inoculation of S aureus in order to obtain osteomyelitis in rabbits. Inoculation of bacteria without sodium morrhuate or vice versa failed to produce an infection.

BACTERIAL CONTAMINATION AND ADHESION, DEVELOPMENT OF INFECTION
Bacteria may reach the bone via the bloodstream, by direct inoculum caused by, for example, trauma or surgery, or by direct spread from an adjacent soft tissue infection (for example diabetic foot ulcer or periodontal disease). Whatever the route of access, bacteria must be able to subsequently adhere to components of the bone matrix in order to start the infection.

S aureus has been known to bind fibrinogen for some decades. This may well provide an explanation for the ability of this microorganism to survive in body fluids. Bacteria clump together and are covered in a layer of fibrinogen, thus protected from host defence mechanisms and antibiotics. However, this alone does not explain how bacteria adhere to bone matrix. Staphylococcus spp express high affinity receptors (adhesins) for fibronectin, collagen, and laminin.

Fibronectin, a glycoprotein found in many body fluids and connective tissue matrices, appears to be particularly relevant to the pathogenesis of chronic osteomyelitis: bacterial adherence to polymers similar to the ones used in orthopaedic surgery is mediated by fibronectin. Fibronectin, fibrinogen, and laminin have been demonstrated to be responsible for adherence of S aureus to the surface of a foreign body in an animal model. The same glycoprotein has been shown to mediate bacterial adhesion to metal plates and screws.

Sublethal doses of antibiotics have been shown to inhibit mucosal adhesion by group A streptococci and Escherichia coli. This is an interesting finding that may provide part of the biological explanation for the efficacy of prophylactic intravenous antibiotics in orthopaedic surgery.

CHRONICITY ASSOCIATED WITH AN IMPLANT
Persistence of bone infection will result in chronic osteomyelitis. The main factors responsible for the development of chronicity are listed in fig 2.

Bacterial persistence is the rule in chronic osteomyelitis associated with a foreign body such as plate and screws or joint replacement. In such cases antimicrobial therapy alone is often unsuccessful, and the infection is cured only by implant removal and debridement of necrotic bone.
Southwood et al, working with an animal model (rabbit) of orthopaedic implant infection, found that as few as 50 organisms contaminating the operative site after a cemented hemiarthroplasty had been implanted resulted in infection, whereas 10,000 organisms were necessary to produce infection in the absence of a foreign body. After adherence on the implant via fibronectin receptors, usually on surface irregularities, coagulase negative staphylococci develop a slimy coat that protects the colony from host defence mechanisms and antibiotics. There is also evidence for a local host defence defect in the pathogenesis of foreign body infection. Polymorphonuclear leucocytes (PMLs) extracted from tissue fluid surrounding a foreign body are unable to kill catalase positive Staphylococcus aureus despite optimal opsonisation. The same PMLs also exhibit a decreased production of superoxide and have lower content of enzymatic granules, an indication of impaired response to infection. The in vitro interaction of PMLs with Teflon leads to respiratory burst and exocytosis of enzymatic granules. The end result is a PML population composed of exhausted cells, with lower granule content, and less killing capacity. A similar study also demonstrated that also the opsonisation of S. aureus in the presence of a foreign body is dramatically reduced at 20 hours. Since S. aureus is mainly killed by opsonisation and subsequent phagocytosis by PMLs, the host defence defects described above are particularly relevant to the development of chronic osteomyelitis associated with internal fixation or joint replacement.

Box 2 summarises the above section.

CHRONICITY NOT ASSOCIATED WITH AN IMPLANT
Chronic osteomyelitis has been shown to result from persistence of the acute haematogenous form in 4.4% of children in a recent Scottish study. Waldvogel et al in 1970 reported development of chronicity in 15% of adults.

Chronic osteomyelitis may present as a recurrent or intermittent disease, with periods of quiescence of variable duration. Relapses of the disease several decades after the acute episode are well known (fig 3). Late reactivation of osteomyelitis up to 80 years after the primary illness had been “cured” have been reported. In a series of 12 patients with a minimum latent period of 20 years, no definite predisposing factor was identified, and both haematogenous and post-traumatic infections seemed equally to be involved.

It is easy to understand the reasons behind the failure of medical treatment of osteomyelitis in the presence of dead bone: the infection will self perpetuate until all sequestra have been debrided. But what causes the same failure of antibiotic treatment in healthy individuals, with normal host defence mechanisms and negative radiology for abscesses or sequestra? And what causes late reactivation? Is osteomyelitis a lifelong disease?

S. aureus, mainly non-encapsulated variants, can be internalised by chick osteoblasts in vitro and survive intracellularly, protected from host defence mechanisms and antibiotics. This might explain the known problem of a flare up of osteomyelitis with no identifiable causative organism. Furthermore, staphylococci can also acquire a very slow metabolic rate, in a phenotypic alteration named small colony variant. Slow growing bacteria have been known to be resistant to antibiotics since 1942, active cell wall synthesis being necessary for penicillin to be bactericidal. Small colony variants of S. aureus were described for the first time in 1932 by Hoffstadt and Youmans as minuscule bacterial colonies (less than 1 mm) that grew very slowly and often required magnification to be seen. Small colony variants were found to be resistant to penicillin one year after its
discovery by Fleming. Small colony variants may indeed account for the frequent failure to identify the causative micro-organism in chronic osteomyelitis: these strains may be easily missed or overgrown in a busy laboratory. They may also account for the frequent clinical presentation of chronic osteomyelitis as a slow, indolent infection that causes little inflammatory response and persists despite prolonged antimicrobial therapy.

Box 3 summarises the above section.

**BACTERIALLY INDUCED OSTEOLYSIS**

During the course of infection, bacteria induce local bone destruction (osteolysis). This aids the spread and persistence of infection and is responsible for the septic loosening of an implant. It is not to be confused with bone loss secondary to ischaemia. An acute infection will cause an intense inflammatory response, thrombosis of endosteal and periosteal vessels, bone infarcts with subsequent abscess and sequestrum formation. A slow, indolent infection will produce a mild to moderate inflammatory response and little or no ischaemic necrosis. A balance will be achieved between bone resorption and new bone formation, and sequestra are less likely to develop.

Osteolysis is accomplished by osteoclasts via stimulation by soluble factors (fig 4). These in turn are produced by immune system cells after interaction with bacteria. Factors such as Gram negative endotoxin, its lipopolysaccharide fraction and N-acetyl-muramyl-dipeptide (MDP) are potent osteolytic factors in vitro. Furthermore, endotoxin and MDP have been shown to stimulate bone resorption in cultured long bones. Staphylococcal surface proteins have a potent osteolytic effect. Surface proteins from *S aureus* can be inhibited by indomethacin, by antibodies to interleukin-1 (IL-1) receptors or tumour necrosis factor (TNF). Surface proteins from *S epidermidis* act by a prostaglandin-independent mechanism, are blocked by a neutralising antibody to TNF-α and only partially by anti-IL-1. Also streptococcal cell wall components can stimulate bone resorption and inhibit protein synthesis in cultured mouse calvariae by a prostaglandin independent mechanism.

The so-called osteoclast activating factor is in fact a mixture of cytokines, of which the most potent is IL-1; TNF and lymphotoxin are less powerful but have a synergistic interaction with IL-1. S-Lipoxygenase metabolites of arachidonic acid also stimulate osteoclasts, and this might offer an opportunity for pharmacological therapy in the future.

Leucocyte derived factors such as TNF induce osteoblasts to cooperate in bone resorption by stimulating osteoclastic activity via a soluble factor. This factor is probably IL-6.

Another recent and fascinating finding is that extracts of *S aureus* and *S epidermidis* cause decreased bone matrix formation in vitro, thereby suggesting that impaired osteogenesis might be an important element of staphylococcal osteomyelitis.

**Conclusion**

Chronic bacterial osteomyelitis remains a major challenge despite advances in antibiotic therapy.

---

**Case report**

A 60 year old man presented with a non-healing wound on his lower leg of several weeks’ duration (fig 3). Inflammatory markers were raised and imaging studies were consistent with chronic osteomyelitis. When he was a child he had successfully undergone treatment for acute osteomyelitis at the same site. The linear scar on the leg is in fact the result of a drainage procedure. The disease had remained quiescent for over 50 years!

---

**Box 3: Persistence of infection 2**

- Chronic osteomyelitis is often a lifelong disease. Late reactivation up to 80 years after the primary episode has been reported.
- Bacteria can also elude host defence mechanisms by hiding intracellularly and by developing a protective slimy coat.
- By acquiring a very slow metabolic rate, bacteria become less sensitive to antibiotics.
- For all the above reasons, operative treatment should be considered whenever possible.

---

**Figure 4 Process of osteolysis. Osteolysis is mediated by soluble factors produced by immune cells after interaction with bacterial antigens. This in turn both increases osteoclastic and decreases osteoblastic activity (LPS = lipopolysaccharide).**
engineering and better aseptic techniques in the operating theatre. Bacteria (predominantly *S aureus* and *S epidermidis*) adhere to bone matrix and orthopaedic implants via receptors to fibronectin and to other structural proteins. They subsequently elude host defences and antibiotics by “hiding” intracellularly, by developing a slimy coat or by acquiring a very slow metabolic rate. The presence of an orthopaedic implant also causes a local polymorphonuclear cell defect, with decreased ability to kill phagocytosed bacteria.

Osteorsis is determined locally by the interaction of bacterial surface components with immune system cells and subsequent cytokine production. Numerous soluble mediators are involved, the end result being both increased osteoclastic activity and decreased new bone formation by osteoblasts.

The increasing development of antibiotic resistance by *S aureus* and *S epidermidis* will probably make conservative treatment even less successful than it is now. A close interaction between orthopaedic surgeons and physicians, with combined medical and operative treatment, is to be commended.

Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often?

J Ciampolini and K G Harding

Postgrad Med J 2000 76: 479-483
doi: 10.1136/pmj.76.898.479

Updated information and services can be found at:
http://pmj.bmj.com/content/76/898/479

These include:

References
This article cites 43 articles, 11 of which you can access for free at:
http://pmj.bmj.com/content/76/898/479#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/